Learn more about whether BioMarin Pharmaceutical Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Company on track to report ELEVATE-44-201 data from first patient cohort in Q2 2026 ---- First patient dosed in ELEVATE-45-201 and the Company ...

Nektar Therapeutics today presented new data from the ongoing REZOLVE-AD Phase 2b study in a late-breaking oral abstract presentation at the American College of Allergy, Asthma & Immunology (ACAAI) ...

With immunology and inflammation blockbusters like AbbVie’s Skyrizi and Rinvoq reeling in nearly $7 billion combined in the ...

What makes plants grow to a certain size? From the tiniest cells to whole leaves, roots, and stems, growth has to be ...

Respeccing in Fallout 4 is a tricky endeavor, especially on console. The base game notoriously has no respec option built ...

When Tucson and the rest of the Southwest baked in record heat this month, the most obvious cause was an overpowering, stagnant ridge of high-pressure air known to weather experts as a heat dome. But ...

SEP-479 Selected as Next-Generation Oral PTH1R Agonist Development Candidate SEP-631 (MRGPRX2 NAM) Phase 1 Clinical Trial in Healthy Volunteers Ongoing Robust Financial Position of $561.6 Million ...

Because it’s costly and cumbersome to transport large structures such as satellite dishes into space, aerospace Ph.D. student Ivan Wu and his ...

In vivo preclinicalproof-of-concept data presented at AHA and ESGCT demonstrating >90% LDL-C reduction in non-human primates supports EDIT-401’s potential as a best-in-class, one-time therapy ...

Positive Phase 1 data for CTX310® presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions and simultaneously published in The New England Journal of Medic ...